Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Non-Current Debt (2017 - 2021)

Sunshine Biopharma filings provide 5 years of Non-Current Debt readings, the most recent being $1.9 million for Q4 2021.

  • On a quarterly basis, Non-Current Debt rose 100.21% to $1.9 million in Q4 2021 year-over-year; TTM through Dec 2021 was $1.9 million, a 100.21% increase, with the full-year FY2021 number at $1.9 million, up 100.21% from a year prior.
  • Non-Current Debt hit $1.9 million in Q4 2021 for Sunshine Biopharma, down from $3.2 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $3.2 million in Q3 2021 to a low of $63234.0 in Q2 2020.
  • Median Non-Current Debt over the past 5 years was $357552.0 (2020), compared with a mean of $1.1 million.
  • The widest YoY moves for Non-Current Debt: up 3148.59% in 2021, down 100.21% in 2021.
  • Sunshine Biopharma's Non-Current Debt stood at $79710.0 in 2017, then surged by 263.63% to $289847.0 in 2018, then dropped by 0.01% to $289825.0 in 2019, then surged by 227.44% to $949006.0 in 2020, then skyrocketed by 100.21% to $1.9 million in 2021.
  • The last three reported values for Non-Current Debt were $1.9 million (Q4 2021), $3.2 million (Q3 2021), and $2.1 million (Q2 2021) per Business Quant data.